Ann: Appendix 4C, page-3

You are correct in absolute terms but a couple of things:

1. I don't think we fully appreciate the organisational trauma AXP went through earlier in the year; staff from 128 to 70, complete restructure of sales and big turnover of sales staff as well as replacement of CEO and Sales VP. Now all that is bedded down.

2. If you go back and listen to the June conference call an investor (me) asked a question about seasonality stating that research in Europe showed a reduction of 20% in breast cancer presentations in the September Qtr over June Qtr (this was a Norwegian study so Nth Hemisphere bias). Frank (the Gorilla) patted me on the head and told me "no!" but started his talk on the US sales in the Qtr with a reference to "sales softness: in the summer. I have referenced this study on HC before.

Overall I expect significant sales growth in the Dec Qtr. 

However I sensed a certain resignation to SP softness from the Q&A in the conference call.